Development of novel zero-order release budesonide tablets for the treatment of ileo-colonic inflammatory bowel disease and comparison with formulations currently used in clinical practiceGareb, B., Dijkstra, G., Kosterink, J. G. W. & Frijlink, H. W., 10-Jan-2019, In : International Journal of Pharmaceutics. 554, p. 366-375 10 p.
Research output: Contribution to journal › Article › Academic › peer-review
- PharmacoTherapy, Epidemiology and Economics
- Translational Immunology Groningen (TRIGR)
- Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI)
- Guided Treatment in Optimal Selected Cancer Patients (GUTS)
- Biopharmaceuticals, Discovery, Design and Delivery (BDDD)
- Targeted Gynaecologic Oncology (TARGON)
- Pharmaceutical Technology and Biopharmacy
Up to 50% of Crohn's disease and ulcerative colitis patients suffer from ileo-colonic inflammation. Topically delivered budesonide is an effective treatment but in vitro as well as clinical data suggest that oral formulations currently used in clinical practice are not optimal to treat the ileo-colon. The aim of this in vitro study was to develop ileo-colonic-targeted zero-order sustained-release tablets containing 3 mg or 9 mg budesonide. Targeted delivery was achieved by coating the tablets with the ColoPulse technology (ColoPulse 3 mg or ColoPulse 9 mg, respectively). Tablets were tested in a 10-h gastrointestinal simulation system for site-specific release, zero-order release kinetics (R-2 >= 0.950), release rate, and completeness of release (>= 80%). Release profiles of the novel formulations were compared with Entocort, Budenofalk, and Cortiment (budesonide MMX). ColoPulse 3 mg and 9 mg were targeted to the simulated ileo-colon, budesonide release was complete and in a sustained zero-order manner, and both formulations complied with a 6-month accelerated stability study. None of the formulations currently used in clinical practice targeted the ileo-colon. These in vitro results are discussed in light of clinical data. ColoPulse 3 mg and 9 mg are novel interesting formulations for the treatment of the entire ileo-colon in inflammatory bowel disease.
|Number of pages||10|
|Journal||International Journal of Pharmaceutics|
|Early online date||8-Nov-2018|
|Publication status||Published - 10-Jan-2019|
- Budesonide, ColoPulse, Drug targeting, IBD, Ileo-colonic, budesonide, generic drug, article, controlled study, drug coating, drug solubility, drug stability, in vitro study, priority journal, sustained drug release, sustained release preparation, tablet formulation, tablet friability, tablet hardness